Fresenius Medical Care: UBS raises target price
(CercleFinance.com) - While confirming its buy rating on the Fresenius Medical Care share, UBS has raised its corresponding 12-month target price from 82 euros to 92 euros, meaning potential upside of over 30%.
According to UBS, Fresenius Medical Care is well positioned to benefit from the boom in home dialysis, which analysts say is underestimated by the consensus.
Indeed, analysts expect a significant improvement in the German group's profitability: they say that the profitability of home dialysis is more than double that in clinics.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.